2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - New Orleans Theatre C
Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Epidemiology, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

798 Multicenter real-world outcomes for relapsed or refractory T-cell/histiocyte-rich large B-cell lymphoma treated with immune checkpoint inhibitors and anti-CD20 bispecific antibodies

Drew Gerber, MD, Paulina Predko, BS2, David Qualls, MD3, Michelle Okwali, MPH4, Efrat Luttwak, Luttwak, MD5, Juan Carlos Ramirez, M.D.6, Yumeng Zhang, MD7, Sirui Ma, MD8, Carrie Ho, MD9, Madiha Iqbal, MBBS, MD10, Julio Chavez, MD11, Iliana Cosio, MD12, Cassandra Duarte, MD13, Andrew Lipsky, MD14, Seda S. Tolu, MD15, Jennifer Effie Amengual, MD16, Barbara Pro, MD17, Hua-Jay Jeffery Cherng, MD18
1 Columbia University, New York, New York, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 UCSF Medical Center, San Francisco, California, United States
9 UCSF Medical Center, San Francisco, California, United States
10 Mayo Clinic, Jacksonville, Florida, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
13 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
14 Columbia University, New York, New York, United States
15 Columbia University, New York, New York, United States
16 Columbia University, New York, New York, United States
17 Columbia University, New York, New York, United States
18 Columbia University, New York, New York, United States

Background: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of diffuse large B-cell lymphoma with distinct biology characterized by an inflammatory, immunosuppressive tumor microenvironment (TME). Relapsed or refractory (R/R) disease is associated with poor outcomes, including after chimeric antigen receptor T-cell (CART) therapy. Given the prevalence of PD-1/PD-L1 expression in TME and PD-L1 amplification, there is biologic rationale for the use of immune checkpoint inhibitors (ICI), supported by case series (Griffin Blood 2021). Outcomes after T-cell redirecting bispecific antibodies (BsAb) are not adequately reported. Multicenter studies are needed to evaluate the real-world outcomes to ICI or BsAb in this difficult-to-treat subtype.

Methods: We conducted a multicenter retrospective study of adult patients (pts) with R/R THRLBCL treated with either ICI or CD3xCD20 BsAb (monotherapy or combination with chemotherapy [chemo]) from 3/2016 to 3/2026 at 7 U.S. centers. Baseline characteristics were captured at time of therapy onset. The primary endpoint was best overall response rate (ORR). Secondary endpoints were CR rate, duration of response (DOR), PFS, and OS. Pts treated with ICI/BsAb as bridging therapy were censored for DOR and PFS at time of CART or transplant. Adverse events (AEs) of interest including immune-related AEs (irAEs), cytokine release syndrome (CRS), and hemophagocytic lymphohistiocytosis (HLH) were captured.  

Results: Thirty-four unique pts were included; 4 received both ICI and BsAb as distinct lines of therapy. Twenty-six (77%) were male, 19 (56%) had primary refractory disease, and 14 (41%) received prior CART. The CR rate to CART was 25% and median time to progression after CART was 1 month.

Twenty-eight pts received ICI (26 pembrolizumab, 2 nivolumab). At time of treatment, median age was 50 years (23-73), 27 (96%) had stage III/IV disease, 18/26 (69%) had elevated LDH, 14/26 (54%) had ≥2 extranodal sites, 18/26 (69%) had an international prognostic index (IPI) ≥3, 19/25 (76%) had bulky disease ≥7 cm, and 13/14 (93%) expressed PD-1. Median prior lines of therapy were 3 (1-8). Most (24, 86%) received ICI monotherapy while 4 received ICI with gemcitabine, vinorelbine, and doxorubicin (N=3) or polatuzumab vedotin (pola), gemcitabine, and oxaliplatin (gemox) (N=1). Median cycles of ICI received were 4 (1-48). ORR and CR rates were 52% and 26%. Three pts with response to ICI proceeded to CART (N=1) or autologous stem cell transplant (N=2).

With a median follow-up of 48.4 months, median PFS and OS were 3.2 and 13.3 months. The 12 and 24-month PFS rates were 29% and 20%. Median DOR was 11.2 months; median duration of CR was not reached, and 83% of pts with CR remained in CR at 24 months. Eight pts (29%) experienced an irAE, of which 4 were grade ≥3, and 5 (18%) experienced HLH. Eight (29%) discontinued ICI for toxicity; one was retreated with ICI 2 years later and experienced CR. By univariable Firth penalized logistic regression, ICI-chemo combination (OR 11.6, p=0.045) and experiencing an irAE (OR 8.3, p=0.018) were associated with ORR. By univariable Cox regression, elevated LDH (HR 2.9, p=0.043) and HLH (HR 5.6, p=0.002) were associated with worse PFS, and irAE (HR 0.3, p=0.013) with improved PFS, acknowledging survivorship bias.

Ten pts received BsAb (4 mosunetuzumab, 3 glofitamab, 3 epcoritamab). At time of treatment, median age was 36 years (30-78), 10 (100%) had stage III/IV disease, 6 (60%) had elevated LDH, 6 (60%) had ≥2 extranodal sites, 8 (80%) had IPI ≥3, 5 (50%) had bulky disease ≥7 cm, and 3/9 (33%) were CD20 negative/weak. Median prior lines of therapy were 3 (1-9). Five received BsAb monotherapy, and 5 with pola (N=3), gemox (N=1), and DHAX (N=1). Three (30%) experienced CRS (grade 1 (2), grade 2 (1)) and 2 (20%) experienced neurotoxicity (grade 1 (1), grade 4 (1)). ORR was 10%, with no CRs. With a median follow-up of 8.7 months, median PFS and OS were 1.2 and 6.5 months; the 6-month PFS rate was 10%.

Conclusion: In this real-world multicenter study of R/R THRLBCL treated with non-CART immunotherapy, ICI led to objective response in 52%, with prolonged remission for pts with CR. Limited activity was observed with BsAb. Though future investigation of ICI combined with chemo or T-cell redirecting therapy in the R/R setting is of interest, curing THRLBCL with frontline therapy remains critical due to ineffective salvage regimens with notable toxicities.
Drew Gerber, MD: No relevant conflicts of interest to declare.